ALL
From the Journals
CLL patients ‘cured’: 10 years post infusion, CAR T cells persist
A decade after CAR T’cell treatment, chronic leukemia patients reported “cured,” with cells still detectable.
Feature
100 coauthored papers, 10 years: Cancer transplant pioneers model 'team science'
MSKCC medical oncologists share expertise in HSCT, Spanish background, a gift for mentoring, and 100 peer-reviewed publications written together...
Feature
DKMS: Small nonprofit to world’s largest stem cell donor registry
A German family’s tragedy launched DKMS, a multinational organization whose goal is to “delete blood cancer.”
Conference Coverage
ASH studies look at racial disparities in ALL care, outcomes
Findings of two studies on U.S. blood cancer care suggest that “structural racism” may play a role in worse outcomes among young Hispanic and...
Conference Coverage
TKI/BiTE combo extends survival of older patients with Ph+ALL
In these elderly patients who are not candidates for chemo, the issue is whether we can prolong remission by the addition of other treatments,...
Conference Coverage
For leukemias, COVID-19 death risks tied to poor prognoses, ICU deferrals
COVID-19 death risks for acute leukemias were driven by poor physician-assessed prognoses and opting out of recommended ICU care.
From the Journals
Customizing pre-CAR T chemotherapy could improve ALL patient outcomes
Findings suggest a way to reduce relapses in patients undergoing CAR T-cell therapy: Tailor pre-CAR T lymphodepleting therapy.
From the Journals
Treating ALL: Asparaginase enzyme levels linked to toxicities
New data suggest benefits of drug monitoring to assess risks for pancreatitis and other toxicities.
From the Journals
Immunotherapies for children with r/r ALL face off
Outcomes were better with tisagenlecleucel vs. blinatumomab in an indirect comparison, but clinical indications should determine which agent to...
Latest News
New trials in leukemia: Could your patient benefit?
Late-phase trials are opening up for leukemia patients aged 1-65 years.
From the Journals
Tolerability doesn’t explain why kids do better than adults on ALL regimens
Differences in tumor biology seem to be at play.